Ero Copper (ERO) announces the remaining assay results from its 28,000-meter Phase 1 drill program at the Furnas Copper-Gold Project, located in the Carajas Mineral Province in Para State, Brazil.

Phuentsholing—With just three months remaining until the scheduled December deadline, the first phase of the Phuentsholing Township Development Project (PTDP) had reached 95 percent completion as of ...

AFSCME union members representing Ramsey County workers are opposing the county’s proposal to close its Detox and Withdrawal Management Program. In a statement last week the AFSCME Council 5, AFSCME ...

Metsera, Inc. (NASDAQ:MTSR) on Tuesday released topline data from VESPER-1 and data from a planned interim analysis for tolerability of VESPER-3 – two Phase 2b trials of MET-097i with potential for ...

VANCOUVER, BC / ACCESS Newswire / October 1, 2025 / Kalo Gold Corp. (TSXV:KALO) ("Kalo" or the "Company") announces completion of the first phase of drilling and the continuation of field programs at ...

Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended ...

Purpose of Study: The purpose of this study is to establish the safety and potential effectiveness of investigational FT819 in participants with moderate to severe systemic lupus erythematosus (SLE) ...

An investigational small-molecule, nonpeptide oral GLP-1 receptor agonist significantly reduced weight in adults with obesity in the randomized ATTAIN-1 trial. At week 72, orforglipron at multiple ...

Aaron Navarro is a CBS News digital reporter covering the 2024 elections. He was previously an associate producer for the CBS News political unit in the 2021 and 2022 election cycles. President Trump ...

Follow this 28-day plan to detox your finances! Learn budgeting, debt reduction strategies, and how to improve your financial health. Start saving and investing today! Who Trump Officials Deem ...

Across both STOP-HS1 and STOP-HS2, povorcitinib treatment resulted in continued clinically meaningful and statistically significant improvements for patients with active moderate to severe ...